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Abstract
Legal status of the new detected uses for old patents as an independent invention is a
problematic issue that gives rise to basic legal challenges regarding patent's promotion
standards of protection, in particular the prolongation of the patent monopoly's term.
International instruments, uncertainties, and a variety of treatments within different national and
regional jurisdictions have increased the complexities of patentability of new uses. These
uncertainties, especially in Agreement on Trade Related Aspects of Intellectual Property Rights
(TRIPS), the most important covenant on commercial aspects of intellectual properties toward
new uses, have resulted in dividing various jurisdictions into contradictory of both proponent
and opponent positions. In this article, a comparative framework has been employed for
analyzing these contradictory treatments, which are mainly founded on “being novel” and “lack
of novelty” through a different sense, i.e. proving act of “creation” via fulfillment the
constructive essentials of “process invention” based on patent law's principles. Within that
context, we employ a framework has been designed for comparison at three levels: the
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international level (TRIPS), regional (European Patent Convention and Andean Union) and
national level (emphasizing on United States' law because of its most consistency with our
sense). In this regard, we are trying to propose an exhaustive and prescriptive criterion that,
while satisfying the essentials of customary patent law, meets the interests of both proponent and
opponent parties. The criterion lies in adjusting the border of constitutional elements of the
process based on desires and interests.
I. Introduction
Patent law has different and practical legal subjects that are an important portion of
industrial property law. Discovery of new uses for old inventions is one of the most problematic
relative issues on the ground. The legal status of new uses, with regard to its direct and indirect
influences on the scope of legal protection of patents and subsequently on economic revenues of
technological innovations, has drawn the attention of many countries in recent years. Today, at
the international level and its modern order, countries can be relatively divided into consumers
(Southern countries) and producers (Northern countries) of technological intellectual properties.
On one hand, the producer countries seek to keep their position, and on the other hand, the
consumer countries seek to lessen the cost of using these products and restrict the producer
countries exclusiveness. In that course, both groups have applied some efforts to meet their
individual interests. The LDCs and some developing countries without productive capacities as
consumers are invoking human right rules, like right to health 1 and, right to development 2 to
achieve their aims. Meanwhile, the developed countries are trying to meet the extravagant
1

World Health Organization, World Intellectual Property Organization and World Trade
Organization “Promoting Access to Medical Technologies and Innovation Intersections Between
Public Health, Intellectual Property and Trade,” 42 (2013).
2
See for example U.N. HRC, high-level task force on the implementation of the right to
development, 6th Sess., U.N. Doc. A/HRC/15/WG.2/TF/2/Add.2. (2010). “Right to development
criteria and operational sub-criteria.”
2

expenditures which they have incurred in the way of producing those products. Subsequent to the
Uruguay round and establishment of TRIPS agreement, the producer member's efforts amounted
to a follow that so-called “TRIPS_plus”. One of the important examples of TRIPS_plus,
especially through the Free Trade Agreements (FTAs) 3, and regional trade agreements 4, is to
provide patent protection for the discovery of secondary applications for known inventions as an
independent patent in order to prolong the term of protection of patents by preventing expired
patents from falling into the public domain. These initiatives are known as a kind of
“evergreening” process and particularly in relation to pharmaceuticals (First/second medical
indications) as a kind of “patent clusters”. 5
The Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH)
defined “evergreening” in regard to pharmaceutical products as such: “When, in the absence of
any apparent additional therapeutic benefits, patent holders use various strategies to extend the
length of their exclusivity beyond the 20-year patent term.” 6
Determining what kinds of new uses, within meaning of TRIPS-plus, are consistent with
customary and essential rules of patent law and TRIPS provisions is one of the questions which
will be answered in this article.

3

See for example Jan. 11, 2006, Free Trade Agreement, U.S. – Bahrain, chapter 14, Art. 14.8.
See for example Trans-Pacific Agreement, United States Proposal, Art. 8.1.
5
For the purpose of delimination, debating on the legal status of old products or processes that
have no physical or chemical change occurred concerning the original invention which for the
subservient uses have presented, is what has been concentrated on. Hence, it does not comprise
other similar topics or other examples of evergreening flow like “incremental innovations” in
pharmaceuticals patents e.g.new forms of old medicaments. See for example Novartis attempts in
India to patent an anti-cancer medicament “Gleevec” which is beta crystalline form of imatinib
mesylate.
6
World Health Organization (WHO), Commission on Intellectual Property Rights Innovation
and Public Health (CIPH), “Public Health, Innovation and Intellectual Property Rights”, (Geneva
2006).
4
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This paper will analyze the various treatments toward new use patents within different
levels (i.e. international, regional, and national) via a comparative frame aimed to gain a
comprehensive picture of the subject and arriving at a conclusion which aims at demarcates an
applicable line between relevant contradictory and various positions that have been taken. This is
intended to give a harmonized, legal approach by setting forth the foundations of patent law. The
following sections will deal with different legal stances that have been taken for the treatment of
claimed new uses in regard medical and non-medical subject-matters in TRIPS agreement,
European Patent Convention and its parallel case law, Andean Union. At the national level, the
emphasis will be on United States' law due to its resemblance to the ultimate conclusion of this
article regarding the necessity of introducing concept of “use patent” within legal concept of
“process patent” through adjusting the borders of constitutional elements of the “process
invention” within territorial jurisdictions.
II. International Instruments as the Main Directive Sources
There is no special procedural or substantive regulation concerning new use patents in
international conventions, treaties and other respective international instruments in relation to the
patent law that obliges the members to protect them or exclude them from protection. 7Moreover,
there is no accepted international doctrine on this matter. The TRIPS agreement as the
exhaustive instrument that plays significant legal and economic role concerning intellectual
property subjects has been preferably selected to be surveyed in this matter.
A. TRIPS Agreement
There is no contractual condition that explicitly or implicitly includes or excludes the
protection of new use patents in TRIPS. Then, at first glance, it seems that the members are free
7

Watal, “Intellectual Property in the WTO and Developed countries “,104 ( Kulwer law
international 2001).
4

to determine their own approach. However, when we refer to Art. 27(1) of the agreement, this
notion is complicated by the requirements set out for conferring patents. In other words, despite
of Art. 1(1) of TRIPS, which introduces the TRIPS provisions as the minimum standards for
protecting the IPRs and leaves the members free to expand their protection beyond these
minimum standards; it simultaneously stipulates that members could not contravene what TRIPS
uncontestably requires. Whereupon the patentability of new uses could be debated only as far as
the requirements and terms of TRIPS patent provisions allow. Hence the fundamental question
is: if the requirements stated in Art. 27(1) are met by the nature of definition of the new use
patents, the conclusion is the protectable contrivance based on the TRIPS requirements, or not?
B. TRIPS's Patent General Provisions
In regards to the methodology behind the interpretation of the international instruments
through the international law, it is well-recognized by the International Court of Justice (ICJ),
and in particular in relation to TRIPS through WTO's Panels and the Appellate Body, that TRIPS
and other respective instruments within WTO's jurisdiction, should be construed based on the
general rules of interpretation of the “Vienna Convention on the Law of Treaties” Arts. 31 and
32 8 as a part of “customary international law”. 9 Therefore, considering Art. 31 of the Vienna
Convention the contexture of TRIPS as the primary interpretative material must be interpreted in

8

See India Patent Protection for Pharmaceutical and Agricultural Chemical Products-United
State, WT/DS50/AB/R, (Dec. 19, 1997) at para. 45; “…The duty of a treaty interpreter is to
examine the words of the treaty to determine the intentions of the parties. This should be done in
accordance with the principles of treaty interpretation set out in Art. 31 of the Vienna
Convention…”
9
The ICJ in several cases has held that those articles considering Art. 38 of the Statute of the
International Court of Justice (SICJ) are part of customary international law. For example,
Kasikili/Sedudu Island (Botswana v. Namibia), 1999 (Dec. 13) at para. 18.
5

“good faith”, in conformity with the “ordinary meaning” to be given to the terms and its
“context” and in consideration of its “object and purpose”. 10
Accordingly, the law first directs us to Art. 27(1) which addresses the basic requirements
of patentability: “Patents shall be available for any inventions, whether products or processes, in
all fields of technology, provided that they are new, involve an inventive step and are capable of
industrial application…”. By a plain reading, it is obvious that Art. 27(1) requires the triple
requirement of novelty, inventive step, and industrial application, while it also restricts the range
of patentable inventions to “process” and “product.” In other words, the primary and
fundamental prerequisite for protecting an invention is being in the format of “process” or
“product” and that condition must be proven prior to the novelty, inventive step, and industrial
application. Nonetheless, the definitions of “process” and “product” have been left without any
specific meaning that members have agreed on. Therefore, for the purpose of determining the
patent eligibility of new uses from the TRIPS perspective, the first step before assessing novelty,
non-obviousness, and industrial application must be to determine whether new uses as
intellectual achievements belong to those entities i.e. “process” or “product” within the meaning
of Art. 27(1) or not. This problem by itself depends on understanding the intended meaning of
these two terms with all other terms harmoniously, contemplating the principle effectiveness in
treaty interpretation (ut res magis valeat quam pereat). 11
From a legal and practical view (and bearing in mind the object and subject of Art.
27(1)) absence of any evidence which indicates a specific meaning of those two terms in

10

Matsushita, Schoenbaum, & Mavroldis, “The World Trade Organization: Law, Practice and
Policy” 35 (Oxford University Press 2006).
11
See Appellate Body Report, Japan Taxes on Alcoholic Beverages-United States
WT/DS8/AB/R (Oct. 4, 1996). See also Yearbook of the International Law Commission (ILC),
Vol. II, at No. 6, U.N Doc. A/CN.4/SER. A/1966/Add. 1 Sales No. 67.V.2 (1966).
6

competent WTO body jurisprudences, decisions or even in travaux préparatoires of TRIPS (As
the supplementary material for interpreting) shows the drafters and subsequently the members
did not intend a meaning beyond the wellknown and prevalent notion of those terms.
On the other hand, unlike the examples of “product patents,” which are related to
tangible, objective and physical entities, quiddity of detecting new uses is some kind of
subjective knowledge and cognition of matters. It is uncontested that the subject matter of new
use patents cannot inherently be represented as a “product”. Moreover, avoiding admixture with
the concept of “discovery”, when we could name someone as an “inventor” that outcome of his
intellectual activities give raises to “creativity”. 12 Thus, the detector of a new use should prove
“creation” of a novel, inventive and useful “process.”
Accordingly, from the TRIPS perspective, the only supposable chance for protecting new
uses is incorporating the concept of “use patent” within meaning of “process patent”. This
necessity arises from the nature of the detecting of new uses is understandable from experiences
of jurisdictions that have protected new uses within their territorial jurisdictions. For example, in
United States and European Patent Office (hereinafter EPO) they just can formulates this as “use
patents” and specifically as the “method of use” and “process of use” patents which both are
categorized as the “process patents” within their jurisdictions. 13
Nevertheless, being that the term “process” in Art. 27(1) in a state that has not been
clearly agreed upon places it in a position wherein it could be interpreted with a broader meaning
than what legally and literally means. This can result in imposing more onerous tasks on
12

Drahos,“ A philosophy of intellectual property” , 29 (Dartmouth1996).
As will be explained in the following parts, it could be deduced as a general rule from EPC's
provisions and EPO's procedures that the new discovered uses must be drafted as “process/use
patent”. The exception to that rule is first and second/further medical indications in Art. 54(4)
and (5) of EPC 2000. The Swiss-type claims for second/further indication also is subject of
general rule. (See infra discussion No. 3.1.1).
13

7

members than what TRIPS requires. Whereupon, in the context of Art. 1 wherein the provisions
of TRIPS are introduced as the minimum standards and considering in dubio mitius principle, the
provision should be construed in a restrictive manner that involves its ordinary meaning, which
would impose less onerous obligations to the parties. From a textualism angle, where applying
the linguistics materials is “the starting point for determining the ordinary meaning of the
terms” 14 the term “process” must be interpreted in a way that provides minimal level of covered
obligations meeting the restrictive principle, which also provides meaningful a face of that term
in favor of the principle of effectiveness. For instance, the Oxford Dictionary defines the term
“process” as “A series of things that are done in order to achieve a particular result”. 15
Nevertheless, via the standards' promotion policies, members could have recourse to the TRIPS
flexibilities applying a particular definition of the term “process” which broadly extends the
protectable items beyond what the term “process” ordinarily means; inter alia “new uses” as one
step activity. 16
Therefore, based on what the Art. 27(1) addresses, members are required to protect new
use patents, provided that a claimed new use fulfills the constructive elements of the “process”
plus proving the triple requirements i.e. novelty, inventive step and industrial application. Hence
the mere detection of new uses for old contrivances, without providing a creative intellectual
steps or in other words without being in the form of “process”, irrespective of what is their nature
(discovery and etc.) should not be considered as a protectable subject-matter.
When an application is posed as a process it must be independently examined in relation
to its previous invention or rather the invention from which the new process was derived. From
14

Panel Report, United States Certain Measures Affecting Imports of Poultry-China,
WT/DS392/R, Sec. VII, 7.259, (Sep. 29, 2010).
15
“Oxford Advanced Learner’s Dictionary of current English”, A S Hornby (8th ed. 2010)
16
Domeij, “Pharmaceutical Patents in Europe”, 130 (Kluwer Law Iternational 2000).
8

here, the relationship between the prior and the newly discovered application will be cut and
subsequently one new, absolute, and protectable invention will be created as the outcome. It is
the affiliation between new detected application and prior patent that truly will result in claiming
the lack of novelty, due to existence in prior art.
Through this approach the monopoly will be restricted to the new discovery made by
inventor. Therefore there will nothing objectionable in granting patent. 17 In other words
allocating rights of each proprietor of the original patent and patentee of the new uses, and
isolating the original invention from its subsequent uses could refute the arguments that have
been articulated supporting contrast between protection of new uses and the TRIPS Anticompetitive provisions. The core of those arguments emerges where the discoverer of new uses
and proprietor of original invention are the same. They argue that it will block the rival
producers (e.g. generic producers of pharmaceuticals) from entry into the market by prolonging
the patent protection term. 18 A response to this concern is that: in the legal sense, irrespective of
the executive difficulties 19, substantively the independence of the original patent from its
subservient uses means that rivals are able to produce the same patented product or use the same
patented process for new uses within the originator's monopoly period and similarly, at the

17

Colston & Galloway, “Modern Intellectual Property Law”, 180 (Routledge 2010).
Musungu & Oh, “The use of Flexibilities of TRIPS By developing countries: Can they
Promote Access to Medicines?” 36 (Commission on Intellectual Property Right Innovation And
Public Health,(CIPIH), Geneva, 2005).
19
Each of new use or original patent’s right holders must where they are claiming the
infringement of their rights prove that litigant have infringed his rights by exploiting the same
product/process. In the realm of medical and pharmaceutical products and in particular
prescription of medicaments to the active ingredient rather than brand of originator, these
executive difficulties have intensified by issues like “off-label use” and “cross label use” of
drugs. See Radley et al. "Off-label Prescribing Among Office-Based Physicians", 166 JAMA
Internal Medicine (2006).
18

9

patent’s expiration date, to produce or use the original invention for its old uses without any
possibility of right infringement or free riding.
C. TRIPS and Patents for First/Second or Further Medical Indications
There are no special features in pharmaceutical inventions which distinguish them from
other inventions that are protectable under the Art. 27(1). In other words the terms of this article
have embodied pharmaceutical inventions. However, Art. 27(3)(a) has given an option to
members to “exclude diagnostic, therapeutic and surgical methods for the treatment of humans or
animals” from patentability. 20 A little scrutiny will show that there is some significant and
conceptual association between Arts. 27(1) and 27(3)(a). As explained above, on one hand the
wording of Art. 27(1) insinuates that new use patents could be protected, if they formulated as
“process”. On the other hand, Art. 27(3)(a) provides the possibility of excluding diagnostic,
therapeutic and surgical methods for treatment. Therefore, logically, the inevitable conclusion of
these two presuppositions is that if each member uses the flexibility given in Art. 27(3)(a), it has
implicitly ruled a prohibition on protecting pharmaceutical new use patents within its internal
law. 21 This is an inevitable result of applying the option given in the Art. 27(3)(a); irrespective of

20

It is not clear that whether these optional exceptions in general sense involve the in vitro
process and prophylactic medical products or not; however it literary seems that Art. 27(3)(a)
could be applied for these procedures as far as they are related to the treatment via therapeutic,
diagnostic or surgical methods.
21
Apart from the probable lexical differences between “method” and “process”, it seems there is
no substantial difference between ordinary meanings of those terms, from TRIPS perspective, as
those are in United States patent law. The arrangement of Art. 27 which based on it, the part 3(a)
(Option of excluding of diagnostic, therapeutic and surgical methods) comes following to the
part (1) (Requirements of granting the patent and being one of product or process) is indicating
those specified methods are some kinds of content of part (1) of Art. 27 i.e. “process”. It is
obvious that “method” cannot be categorized as the subset of “product” inventions, attending to
its lexical and real nature of the term “method”.
10

whether it complies with members' interests that have adopted it, or not. However, for countries
which have no sophisticated pharmaceutical R&D, this may be advantageous. 22
Given the above, in this regard, the United States' performance, as a member of TRIPS in
its respective legislations is most commensurate with Art. 27 of TRIPS. In the United States, the
“therapeutic, diagnostic and surgical” method of treatment have not been excluded from
protection, while their protection has been suspended on formulating their claims within meaning
of “process.” 23
The European countries' approach regarding “diagnostic, therapeutic and surgical
methods” in European Patent Convention (hereinafter EPC) where in the majority of its member
states are also members of TRIPS is interesting. 24 Generally, in spite of exclusion, these method
of protection by the EPC's provisions, the protection of medical new uses (Including first and
second medical indications), by means of complicated jurisprudences (Purpose-related product),
has been provided for. The remarkable point in this regard is that the current procedure of the
European Patent Office (EPO) for protecting non-medical new uses and its previous procedure
for protecting medical second indications (Swiss type claim) 25 both require that new uses must
be claimed within the process format. This is unlike the current EPC's approach (Purpose-related
product patent) wherein second medical indications just like first indications are patented as
product rather than process. 26

22

Drahos, “Developing Countries and International Intellectual Property Standard-Setting”, 23
(Commission on Intellectual Property Rights (CIPR),Geneva, 2002 ).
23
UNCTAD-ICTSD Project on IPR and Sustainable Development, “Resource Book on TRIPS
and Development”, 384 (Cambridge University Press, 2005).
24
There are only three countries including Monaco, San marino and Serbia that are EPC's
member whilst have not acceded to WTO.
25
See discussion infra 3.1.1.1.
26
See the case, T 1099/09 Coloplast /device for treatment of urinary incontinency, (Jan. 12,
2012).
11

Such a verbatim reading of relevant TRIPS regulations that restrict the protection’s scope
of pharmaceutical new uses in essentials of customary patent law, considering the proven
adverse influences of protecting of mere discovered pharmaceutical and therapeutic new uses on
produce capacities for traditional medicines, preservation of bio-resources 27, access to
medicines 28, medicines price 29, and subsequently on public health. This is more commensurate
with “Doha declaration” (Declaration on TRIPS Agreement and Public Health) 30 as an
instrument which essentially has been agreed upon, to be applied for interpreting and
implementing the requirements of TRIPS in a way that improves members' public health.
Paragraph (4) of this declaration states: “…we affirm that the Agreement can and should be
interpreted and implemented in a manner supportive of WTO members' right to protect public
health and, in particular, to promote access to medicines for all.”
III. The Regional Instruments
In regard to the number of obligators, the regional instruments of intellectual properties,
after internationals, could have a significant importance in opening ways to harmonize various
national treatments toward subjects concerning patent law. There are many regional instruments
in particular that concern patents that do not oblige their members to protect new uses. For

27

Correa, ”A Guide to Pharmaceutical patent”, 138 (South Centre 2008).
Gaëlle, “New trends in IP protection and health issues in FTA negotiations” in: Coriat, “The
Political Economy of HIV/AIDS in Developing Countries. TRIPS, Public Health Systems and
Free Access ”, 56 (Edward Elgar Inc. Cheltenham, UK & Northampton, MA, USA 2008).
29
The Case of price growth of depression medicament “Fluoxetine” subsequent to patent its
second application treatment premenstrual dysphoric disorder. See supra note at 130. See also
Vernaz et al. “
Patented Drug Extension Strategies on Healthcare Spending: A Cost-Evaluation Analysis”,
PLOS Medicine,(2013).
30
World Trade Organization (WTO), Ministerial Declaration of 14 November 2001
WT/MIN(01)/DEC/1, 41 I.L.M 746 (2002).TRIPS on Agreement and Public Health(Doha
Declaration), Nov. 14, 2001, Para. (6),.
28
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instance, the “EPC” as a regional convention, and the “Andean Union” 31 and “Gulf Cooperation
Council” (GCC) 32 as regional unions are the only regional entities which have responded to the
issue of new use patents within their jurisdictions.
A. European Patent Convention (EPC)
There is a bifurcation concerning new use patents in the EPC and its parallel judicial
precedent in EPO based on subject matter of contrivances. Hence, the protection regime for
pharmaceutical new uses (including first and second medical indications) has been separated
against non-pharmaceutical new uses and has special conditions. That dualism dealing with
medical and non-medical new uses, has emanated from the revision of the EPO's procedures and
also the EPC 1973 in 2000, which amounted to creating two independent and equal legal
processes.
1. Medical New Uses (First/Second or Further Medical Indications)
Within EPC's jurisdiction, the rules toward medical new uses can be divided into two
periods of before and after the revision of the EPC. Because the revision of the EPC was in
reaction to previous gaps and loopholes that existed in EPC 1973 and also existed in the
unrevised EBA regulations concerning second medical indications (Swiss type claim) was an
indirect inspiration for law of some non-European jurisdictions like Japan, 33 Australia, 34 New

31

The Andean Community as a customs union which comprises the South American countries,
Bolivia, Colombia, Ecuador, and Peru. The trade bloc was called the Andean Pact until 1996 and
came into existence with the signing of the Cartagena Agreement in 1969.
32
Gulf Cooperation Council (GCC) as a political and economic union which comprises the
States of United Arab Emirates, Kingdom of Bahrain, Kingdom of Saudi Arabia, Sultanate of
Oman, and State of Qatar. Established on 25 May 1981.
33
Supreme court of Tokyo, Heisei, 10 (Gyō Ke) 401, 2001, April 25.
34
Bristol-Myers Squibb Co v. F H Faulding & Co Ltd (2000) 41 I.P.R.467 (Fed.ct.Aus.,TD).
13

Zealand, 35 Philippine, 36 Canada, 37 China, 38 Israel, 39 and Singapore 40 and at the regional level
GCC 41. As a result it is important to analyze both forgoing periods.
a) EPC 1973: The Primary Ban and Making a Standard Solution
The EPC 1973 did not have any provision that endorsed the patentability of the second
medical indications, unlike the first indications. Hence, the EPO would frequently show its
distaste of patenting second/further indications through literal interpretation of Art. 52(4) of EPC
1973, which had excluded methods for treatment of any human or animal bodies by surgery or
therapy, and diagnostic methods practiced on the human or animal body. 42 This stipulation had
been based on ethical or moral reasons. 43 At the highest level, legal problems associated with the
patentability of claims to the new use of a known compound, provided the subject matter for the
first seven Decisions to be issued by the Enlarged Board of Appeal, namely G 1-7/83.

35

Pharmaceutical Management Agency Ltd v. Commissioner of Patents [2000] 2 NZLR 529
(Pharmac).
36
Intellectual Property Office of the Philippines (IPHL), Examination Guidelines For
Pharmaceutical Patent Applications Involving Known Substances, Part 9
37
Canadian Intellectual property Office (CIPO), Manual of Patent Office Practice (MOPOP),
Chapter 12, Sec. 12.06.08 & 12.06.08d.
38
State Intellectual property Office of the People's Republic of China (SIPO), Guidelines for
Patent Examination (2010), Part II, Chapter 10, Sec. 4.5.2.
39
Israel Patent Office, 1993, Directive No. 38 and No 40.
40
Singapore’s Patents Act (Revised Edition 2005, as amended up to the Statutes (Miscellaneous
Amendments) Act 2014), Sec. 14 (7).
41
GCC Patent Office, patent no. GC 0001215, claim 27, “Use of the compound defined in any
one of claims 1 to 23 for the treatment or prophylaxis of a disease modulated by LXR alpha
and/or LXR beta agonists “, published in GCC patent gazette no. 14. 30 September 2010. See
also supra note 33.
42
Ventose,”Patent Protection for Second and Further Medical Uses Under the European Patent
Conventio”, 6 SCRIPTed 7(2009).
43
United Nation Conference on Trade and Development (UNCTAD) and International Center
for Trade and Sustainable Development(ICTSD) Project on IPR and Sustainable Development,
“Resource Book on TRIPS and Development”, 384 (Cambridge University Press, 2005).
14

Historically, making an appropriate legal action was initiated toward first indications, in
HOFFMANN-LA ROCHE/Pyrrolidine derivatives. 44 The claimed subject matter was to apply a
non-medical substance as an active substance to combat cerebral insufficiency and improve
intellectual ability. The technical board of appeal (hereinafter TBA) held that, ”the principle of
equal treatment would require that an inventor who for the first time makes a known compound
available for therapy should be correspondingly rewarded for his service with a purpose-limited
substance claim under Art. 54(5) EPC to cover the whole field of therapy”. 45
The TBA also observed that, in first medical indications, novelty will not only be
destroyed by existence of same specific therapeutic effects in prior art, but also by existence of
any other therapeutic application that would be disclosed. By that policy a monopoly was made
over whole therapeutic applications that first medical indications might have contained and
subsequently the novelty for second/further uses that could be discovered in the future was
destroyed. In the case G 5/83 (EISAI/Second Medical Indication), which was issued after the
TBA'S referred question 46, the patentability of first and second medical indications, in view the
prohibitions of the Art. 52(4) EPC 1973 had legally been challenged. The core of the question
was: “Can a patent with claims directed to the use be granted for the use of a substance or
composition for the treatment of the human or animal body by therapy?” 47
The EBA's response included two parts; the major part was concerned with
second/further medical indications and minor part dealt with first indications. For first

44

T 0128/82.
Id, at para. 10.
46
T 0017/81, Bayer/Nimodipin.
47
G 05/83, EISAI/Second medical indication, at para. 1.
45
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indications the EBA confirmed that under Art. 54(5) EPC 1973(Now Art. 54(4)EPC) 48, “The
inventor of a first medical indication can obtain purpose-limited product protection for a known
substance or composition, without having to restrict himself to the substance or composition
when in a form technically adapted to a specified therapeutic purpose. The appropriate protection
for him is, therefore, in its broadest form, a purpose-limited product claim. 49 In fact, the EBA
made it a possibility for inventing the second/further medical indications for pharmaceutical
products, which had been previously protected as first medical indications. This was not possible
based on former TBA's jurisprudence. The case Bayer/Pyrrolidine-Derivatives had provided a
monopoly over all existed but not still discovered medical applications in relevant substances
and compositions. 50
The bridge between provisions of first and second medical indications in the EBA's
decision was that both had to be formulated as a “use claim” which is not constitutionally
different from “method claim”. 51 Non-substantial differences between “method” and “use”
claims made a big obstacle for protecting of second indications through the direct contradiction
to the prohibition that ruled against protection of therapeutic, surgical and diagnostic methods;
unlike the first indications. Thereby, claims which were directed as “Use of a substance or
composition for the treatment of the human or animal body by therapy” 52 had an identical legal
effect in comparison with claims were directed as method for treatment of the human or animal

48

The Art. 54(4) EPC 2000(The former 52(5) in EPC 1973) expresses: Paragraphs 2 and 3
[Requirements concerning novelty of novelty] shall not exclude the patentability of any
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body by therapy and subsequently were contrary to the Art. 52(4). The EBA had to contemplate
the benefits of second medical protection while it also had to consider the barriers of EPC.
Hence, the solution that could satisfy both of those interests should be devised. From a legal
perspective, the EPO was faced with two basic problems. First, the problem of proving “novelty”
just for a “use” in medical products which existed in prior art, bearing in mind the absolute
definition of “novelty” which had been provided in Art. 54(1),(2) and (3). 53 Second, the
confliction between second medical indications as use/method claims with specified methods in
Art. 52(4). The EBA’s solution emanated from the Swiss Federal Office for Intellectual Property
statement of practice regarding "use claims.” 54 The Swiss solution model led to birth the of the
"Swiss type claim,” which was directed as "the use of a substance or composition for the
manufacture of a medicament for a specified new and inventive therapeutic application". By
Swiss formulation, which was no less than an ingenious circumvention, both foregoing legal
difficulties were solved. By that formulation the impediment of required “novelty” was met by
extracting it from special purpose of use of the relevant substance or composition. Thereby, the
relationship between claimed subject-matter and the existence thereof in prior art was
discontinued by constituting new and independent novelty (i.e. one which is derived from new
therapeutic purpose of use not from method of use or the substance or composition per se.)
Hence, the claim must be directed to a known medicament to treat a malady not previously
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Art. (54):
(1): An invention shall be considered to be new if it does not form part of the state of the art.
(2): The state of the art shall be held to comprise everything made available to the public by
means of a written or oral description, by use, or in any other way before the date of filing of the
European patent application.
(3): Additionally, the content of European patent applications as filed, of which the dates of
filing are prior to the date referred to in paragraph 2 and which were published under Art. 93 data
shall be considered as comprised in the state of the art.
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treated via that substance or composition. In its decision, the EBA justified through analogy the
requirement for novelty of first medical indications. 55 The EBA stated that the content of Art.
54(5) 1973 toward protection of first indications does not mean that alternative i.e.
second/further medical indication has been excluded and that this kind of interpretation i.e.
“expressio unius (est) exclusio alterius” is not applicable here. 56 Thereby the EBA extended the
notion of novelty provided for in former Art. 54(5) EPC 1973 to apply to each further medical
use.
The next essential element of the Swiss-type claim was devised for resolving the conflict
between the second/further indications as a plain use/method claim with Art. 52(4) 1973, “use
for manufacture of a medicament”. 57 In practice, if a claim simply is formulated as the use or
method of applying of a known medical substance or composition for therapy, it would be in
direct conflict with the exclusion of methods of treatment; unless the substance or composition's
new and direct therapeutic use or method of use could be transformed into indirect therapeutic
use or method of use via a proviso of “manufacture.” For that purpose the way of using
substance or composition for manufacture/preparation must be explained in the claim as
indicating “the sequence of steps being implied” 58 for manufacturing a “prophylactic” or
“curative” 59 “chemical substance or composition,” 60 which is used for treatment of a disease or
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60
T 0004/98, Liposome Compositions, at 8.1; (Aug 9, 2001).
56

18

disorder within meaning of treatment by “therapy.” 61For that purpose the claimed medicament
“[must be] brought into contact with the body in order to deliver and apply a substance or
composition in an effective form and dose for it to develop its therapeutic effects within the
patient's body.” 62
After establishing this preliminary legal framework for second medical indications within
the meaning of (EISAI/Second Medical Indication) the breadth of items that can be brought up as
protectable second medical indication was expanded to the subjects like new route of medication
administration 63, treating the same disease in a new way by using known product (New dosage
regimen/method of administration) 64 treatment of the same receptors for the same disease by the
same medication for a group of those with different physiological or pathological status 65, and
different technical effect which is leading to a truly new application. 66
Finally, in 2010, the EBA stipulated that the Swiss type claim format is no longer the
correct format for subject matter of claims that are rendered novel only by a new therapeutic use
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For details in regard to meaning of “therapy” within EPO's jurisdiction, see supra 58 and infra
65.
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Supra note 56, at 2.5.
63
T 0051/93, HCG/SERONO, (Jun. 8 ,1994);related to “Use of HCG for the manufacture of a
non- depot medicament for use in the treatment by subcutaneous administration of infertility or
male sexual disorders.”
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T 1020/03, Method of administration of IGF-I/GENENTECH INC., (29 Oct. 2004).
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T 0019/86, Pigs II, (Oct. 15, 1987); related to the therapeutic use of a vaccine (Attenuated
Aujeszky-virus) which was known for treatment of sero-negative pigs for pigs that are seropositive.
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T 0290/86, Cleaning plaque, (Nov. 13 1990); related to the two independent claims concerned
with using same composition( Lanthanum salts) for same therapeutic purpose (Prevention of
tooth decay) with different (New and inventive) technical effect, including using one of them for
removing plaque and another for solubility of tooth enamel.
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of a medicament. 67 The board was of the opinion that the loophole was existed in EPC 1973, has
been closed, thus ratio decidendi “when the reason of the law ceases, the law itself ceases.” 68
The recent TBA's decision in the H.Maatalous Oy/food additive 69 shows continuous
endeavors to determine the extent of applying the G 5/83 (EISAI/Second Medical Indication) in
new cases. In this case, the patent was within the veterinary science area and pertained to a feed
additive which is prepared by hydrolytically treating a yeast raw material with an acid, for the
prevention of intestinal diseases and/or promotion of growth. Subsequent to any opposition
against the patent 70 and filing an appeal for opposition division's decision to maintain the patent
in amended form 71, the TBA considered and ruled in a milestone decision to apply the
(EISAI/Second Medical Indication.) 72 The error that the board specified to be amended was in
regard to a claim for both first and second/subsequent medical indications for the same subjectmatter. A part of claim was directed as “The procedure for preparing a feed additive, to be used
for the prevention of gastric disorders and intestinal diseases…” 73 which was in accordance with
a form of a second medical use (EISAI/Second Medical Indication) and simultaneously, the claim
was characterized as "Feed additive for the prevention of intestinal diseases …” by analogy with
Art. 54(5) EPC 1973. The board concluded that if the claimed subject-matter indeed relates to
the first medical indication, then G 5/83 would provide no legal basis to additionally claim the
same subject-matter in terms of a second medical indication. In other words, the legal fiction that
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G 2/08, Dosage regime/ABBOTT RESPIRATORY, (Oct. 29, 2004).
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G 5/83, namely that the therapeutic treatment according to Art. 52(4) EPC 1973, is a limiting
feature applies only if a therapeutic treatment is a second/further medical indication. 74
b) EPC 2000: Eradication of the Legal Uncertainties
After the EPC 1973 revision and the establishment of its 2000 version, 75 the legal status
of second/further medical indications was determined unambiguously. Thereby, former Art.
54(5) EPC 1973 ("first use in a medical method") was renumbered to become Art. 54 (4) EPC
and a new Art. 54(5) EPC was introduced enshrining the former judicial case laws to provide
protection for each second/further medical uses. It expressly regulates:
Paragraphs 2 and 3 [Requirements concerning novelty of novelty] shall also not
exclude the patentability of any substance or composition referred to in paragraph
4 for any specific use in a method referred to in Article 53(c), [therapeutic,
surgical, diagnostic] provided that such use is not comprised in the state of the art.
Unlike the Swiss type patent that was applied to process/method patents and for any
medical methods in a way which provides broad (Generic) protection, the purpose limited
product patents have been given only for the triple medical methods of Art. 53(c). Hence, the
scope of items that Art. 54(5) of EPC 2000 covers will be restricted in comparison with the
Swiss type claims which could be used for any kind of medical uses. In other words they provide
equivalent legal protection as far as they overlap with each other toward medical methods within
meaning of Art. 53(c). However, the extent of conferred rights and means of enforcement could
be extended by changing the patent category from process patent into product patent trough
restrictions on the freedom of medical practitioners to prescribe or administer generics. Thereby
by supposing (Legal fiction) that the detector of new second/further indication has initially
invented the subject-matter as a product, which is specially used for specific medical applications
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Id, at para. 3.3.
EPC 2000 became into force in 13 December 2007.
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the subject-matter will be separated from its prior existence. In other words, novelty is derived
from the substance or composition itself and the new and inventive purpose of use will separate
the subject-matter from its old identical existence. Accordingly, the legal status of first and
second indications has currently been converged. Therefore, it could be said now that the same
rationales that have been applied for justifying the first indications (Purpose-limited product)
could be used for second/furthers.
By transforming the legal nature of the second medical indications i.e. from a process
invention into product invention, enforcing the rights thereof has changed. Strictly speaking ,
irrespective of facts which could be varied from case to case, the person who has alleged
violation, must prove a directly or contributory infringement for a product rather than a process,
which has its special conditions, de jure. 76 In fact, since a patent will be issued subsequent to the
inventor's creative act, the title of patent which determines the span of his/her rights must be in
accordance to what he/she has created. Hence, even though issuing a “product patent” for first
and second medical indications through purpose-limited product strategy seems legally
justifiable, it is not within following the inventor's real creation i.e. “use.”
Judicial bodies’ decisions in the past have indicated a prudent treatment toward
second/further medical indications. Since the context of paragraph (5) of Art. (54) is an
exemption to prohibitions that are ruled in Art. 53(c) both are logically construed Expressio
unius in relation to each other according to their strict text. This can be found from the
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Art. 64(3) states: “Any infringement of a European patent shall be dealt with by national law”.
For example the UK legislature have provided that:
(a) Where the invention is a product, he makes, disposes of, offers to dispose of, uses or imports
the product or keeps it whether for disposal or otherwise;…
(c) where the invention is a process, he disposes of, offers to dispose of, uses or imports any
product obtained directly by means of that process or keeps any such product whether for
disposal or otherwise. (Patents Act 1977, Chapter 37, sec. 60)
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preparatory documents of EPC 2000, in particular the Swiss delegation's proposal which was
eventually adopted by the Diplomatic Conference and constitutes the current version Art. 54(5):
The decisive aspect of paragraph 5 of the Swiss proposal was that protection
would only be granted for a “specific use” if it did not yet form part of the state of
the art. The aim, therefore, was to provide narrow protection for the second
medical indication and broad protection for the first indication. 77
The TBA decision in Coloplast regarding a device for treatment of urinary incontinency 78
is a good example. In that case, the claimed subject-matter regarded an implantable device
(Biocompatible material) designed for use in treatment of urinary incontinence in women. The
TBA's narrow and literal interpretation restricted the range of Art. 54 (5) only in products which
are composition and substances. The EBA clearly observed that “the distinction made by the
legislature is not between substances and compositions but between products which are
substances or compositions and products which are not.” 79
2. Non-medical New Uses
There is no applicable regulation that determines the legal standing of nonpharmaceutical
new use patents, whether it is in E.P.C 1973 or in E.P.C 2000. Those uncertainties were removed
by case law and by the EBA in the case Mobil/Friction. 80 In that case the claim was the use of a
known substance as a friction reducing additive in lubricants. The substance was already known
to inhibit rust, and the application was therefore refused based on lack of novelty. Consequently
“Mobil” decided to amend the application from the claim for a “compound” into the “use of that
compound in a composition for specified purpose”, which was accepted by EBA. Finally, the
EBA having regard to the importance of technological applicability of innovations within EPO's
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jurisdiction, 81 held that if a claim was to the use of a known substance in a new way (means of
realization) 82 for a new purpose, then it might be novel and inventive because the new way of
using the substance created a technical result (technical realization.) In contrast, a claim for the
use of a known substance in a known way to achieve a new purpose will not include any novel
technical feature. 83 Clearly, the product claim could not succeed, as the substance was not new. 84
The EBA affirmed this matter, stating:
There are basically two different types of claim, namely a claim to a physical
entity (e.g. product, apparatus) and a claim to a physical activity (e.g. method,
process, use) . . . . The technical features of a claim to a physical entity are the
physical parameters of the entity, and the technical features of a claim to an
activity are the physical steps which define such activity. 85
In addition, within EPO's jurisdiction there are two different types of process claim, (i)
The use of an entity to achieve a technical effect and, (ii) A process for the production of a
product. 86 Whereupon, there is no constitutional difference between “use claim” and
“method/process claim” and as EBA ruled, each of them can be formulated interchangeably,
within EPO's jurisdiction. In actuality, a “method/process” implies an activity which consists of
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For instance, what has been ruled at para. 7 of decision G2/88 shows the EBA’s tendency,
emphasizing on the background role of industrial susceptibility in determining novelty within
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“setting out a sequence of steps” while a “use” implies an activity that involves “a sequence of
steps being implied.” 87
When those rules are pieced together like puzzle fragments, it is obvious that the new
use claims should fall into physical activity claim types, wherein their technical features are the
physical steps that define such activity within a sequence of steps which have been employed. In
other words there should be a series of objective and constructive steps which amount to a
technical effect, to constitute a patentable new use as subject-matter and subsequently to
distinguish them from the concept of mere discoveries.
B. The “Andean” Experience
The story began in the mid-1990s when the majority of the Andean member countries
including Peru, Venezuela and Ecuador except Colombia decided to grant patents for newly
discovered uses (Treatment male impotency) for cardiovascular medicament
“pyrazolpyrimidinones” to an American multinational pharmaceutical corporation Pfizer. The
Colombian authorities in “Superintendence of Industry and Commerce” rejected the Pfizer
application through its specific interpretation from Art. 1 of Andean's decision 344 which states:
“The Member Countries shall grant patents for inventions in all areas of technology, whether
goods or processes, those are new, involve an inventive step and are industrially applicable.”
The Colombian authorities argued, that Art. 1 only involves “goods” and “processes” and
does not permit the patent protection for “uses”. Eventually and subsequent to the presidential
decree which permitted second-use patents in Peru, the Association of Pharmaceutical Industries
of National Origin and Capital (ADIFAN,) fielded a compliant with the Andean General
Secretariat. With the Secretariat's support, the case was submitted to the Andean Tribunal of
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Justice (hereinafter ATJ). 88 The ATJ's verdict had the same result provided by the Colombian IP
agency. The difference was in materials what ATJ had employed reasoning its judgment. The
ATJ's judgment, which was based on Arts. 16 and 21 of Decision 486 that duplicated Arts. 2 and
16 of Decision 344, clarified the Peruvian decree and meanwhile other new use conferred patents
by other members had violated Andean common intellectual property regime. 89 Art. 21 of
Decision 486 requires the members:
Products or processes already patented and included in the state of the art within
the meaning of Article 16 of this Decision may not be the subject of new patents
on the sole ground of having been put to a use different from that originally
contemplated by the initial patent.
Art. 16 also defined the novelty requirement as:
An invention may be deemed new when not included in the state of the art. The
state of the art comprises everything that has been made available to the public by
written or oral description, use, marketing, or any other means prior to the filing
date of the patent or, where appropriate, of the priority claimed.
Generally speaking, it could be understood that the ATJ's argumentation, alongside Art.
21, which references novelty's definition within meaning of Art. 16 and also existence of the
former patent in Non-Andean community country, entails the acceptance of “absolute novelty”
which was acknowledged in “pipeline patents” case. 90 In fact rejection the new use patents based
on lack of novelty as the general rule without specifying geographical criteria for novelty,
requires the original product or process not only in jurisdiction which the rule has been sought
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but also in any other jurisdictions have not been yet patented. Whereas, if it has already been
patented it would be posited that the subject matter had been patented for all its uses.
Moreover, the Andean legislature, like many of other silent and opposed jurisdictions,
has not clarified what kind of uses it intends and what fills the gap between “process” and “use”
concepts. In other words, it has not specified any indicative criteria which would separate the
concepts of “process” and “use”. For example, it is not clear whether a claim for a new use of an
old invention could be directed in a manner in which the new use results from a series of steps,
would be considered as a “process claim” or as a “use claim.”
Admittedly, extending the concept of processes in a manner that involves the uses works
to “strengthen the industrial property rights” as permitted in Art. 143 of Decision 344. However,
the ATJ's construction on Art. 143 in the “pipeline patents” forbids this conclusion by holding
that the term “strengthen” must be interpreted in a teleological fashion that supportively
complement regional IP system, not contradict it. 91
IV. National Laws' Treatments
At this level, countries irrespective of their level of development could be divided into
countries with silent, opponent and proponent domestic laws. The LDCs countries have totally
fallen into the category of countries with silent laws. Studies show that in developing countries,
in the majority (55%) of the laws reviewed, there is no specific exclusion regarding protecting
new uses. 92 These countries include: Thailand, 93 Pakistan, 94 India, 95 Dominican Republic, 96
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Uruguay, 97 Philippines, 98 Mexico, 99 Oman Andean pact 100 (Bolivia, Colombia, Ecuador, and
Peru) are part of developing countries’ group with oppositional domestic laws. Some developing
countries like Malaysia, 101 China, 102 South Africa, 103 pact GCC 104 have domestic laws just for
second medical indications through Swiss-type claims and in some countries, like Chili 105 and
Ukraine, 106 laws cover all claimed new uses (medical and non-medicals.) 107 The vast majority of
developed countries recourse Swiss-type claim for protecting second medical indications and
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some of them, like United States and Canada, 108 have identified legal protection for both of
medical and non-medical new uses.
In the countries with silent domestic laws the factor that causes uncertainty is how they
treat new uses, whether legally the “process” includes “uses,” 109 or more basically, whether
“uses” are protectable subject-matters or not. Although, the common point of view for
sanctioning the protection of new uses in opponent countries is absence of novelty. 110 In fact,
despite of reasons like lack of novelty, inventiveness and industrial application which can be
applied for treating some cases of new uses, it could be argued that this application could give
rise to a non-comprehensive approach that does not account for all probable and potential cases
that have been intended for prohibition. Similarly, in jurisdictions with proponent stances the
plain protective laws without clear criterion for protecting new uses can place them in the same
situation that may cause arbitrary results in extending the scope of protection beyond those
jurisdictions’ legislative intent. By way of example, in the medical realm, presuming protectability of therapeutic methods where the claimed subject-matter is a new medical use that has
been obtained by means of changing a specific dosage regimen, (Same dosage, for known
medicament e.g. every 12 hours) the prime object that must be examined prior to the novelty,
inventive step and industrial application is legal conformity between applicant's chosen
framework for claimed subject-matter and requirements of requested type of patent within
relevant jurisdiction. In other words, when presented with a new use application, the first stage
that the examiner in determining patentability has to consider is protect-ability of formulation
108
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posed by the claim. In that case, the plain protection toward new uses without delineating the
elements which legally constitute a “Process/Use invention” will amount to ambiguity in
determining whether changing a schedule of doses of a therapeutic agent per unit of time as
heuristics could constitute a protectable invention which is differentiable from an abstract idea.
Similarly, plain opposition or opposition founded on the lack of each foregoing triple
prerequisites does not determine whether a dosage regimen as a new use for old medical product
is protectable subject-matter. Because the prime question here is not whether the dosage regimen
is novel, inventive and industrially applicable, rather logically it is whether the claimed dosage
regimen has met the “use/process” patent's legal essentials or not. When that conformity has
been proven, examining for other requirements like novelty should be done at the next level of
examination and in relation to the prior uses/processes included in respective prior art; not in
association to the product which has claimed a new use. Therefore, when the conformity of
chosen frame for claimed new use is done, the first phase of examination is accomplished, and
examining the novelty and other requirements as second phase of examining the subject matter
as what is independent from former inventions what it derives from will be begun.
In comparison to the EPO's experiences, the TBA's bewilderment regarding extension of
Art. 52(5) in Dosage regime/ABBOTT RESPIRATORY toward meaning of “specific use” in
relevant prior art is an example of plain protection that does not clearly specify the borders of
protectable new uses. The TBA, in need of clarification, asked the EBA to determine the protectability of a claim that was directed to a novel and inventive method of therapeutic treatment (in
that case specific dosage regimen) via using the same medicament which was known treating the
same illness. In spite of the EBA's final positive response, which reasoned that Art. 52(5)
requirement of “specific use” does not exclude using the same drug treating the same illness,
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acknowledged “[I]t does not define any degree of distinctiveness the new use would be required
to have in order to qualify as a specific use within the meaning of that article.” 111
At this level, the legislature of United States has adapted the nearest approach to our
point of view stating: “The term “process” . . . includes a new use of a known process, machine,
manufacture, composition of matter, or material.” 112 In other words, if the new uses for known
process, machine, manufacture, composition of matter, or material is not posed as “process” then
it should not be considered protectable subject-matter. 113 This is what the United States Patent
and Trademark Office's (USPTO) Manuel of Patent Examining Procedure (MPEP) categorizes as
a separate subset for “process patent” with special requirements as “process of use patent.” 114
Within precedent, this language could be traced back to the opinion of Privy Council in
Boulton v. Bull, 115 wherein an inventor (David Hartley) had claimed using iron plates for
securing buildings against fire. The Lord Eyre, C.J. said: “When the effect produced is no
substance or composition of thing, the patent can only be for the mechanism, if new mechanism
is used, or for the process, if it be a new method of operating, with or without old mechanism, by
which the new effect is produced.”. While the Federal Circuit in Atlas Powder Co. v. Ireco
Inc. 116 held that: “[T]he discovery of a previously unappreciated property of a prior art
composition, or of a scientific explanation for the prior art’s functioning, does not render the old
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composition patentably new to the discoverer.” On the other hand, in In re Hack 117 the Court of
Customs and Patent Appeals ruled: “[I]t is obvious that such use can be nothing other than a
method or process. As a matter of claim drafting, therefore, the discoverer of a new use must
protect his discovery by means of process or method claims and not product claims.”
Therefore, claiming a new use, new function or unknown property which is inherently
present in the prior art, does not necessarily make the claim patentable 118 unless it shows a
“useful, concrete, and tangible” result 119 which is claimed in “process of using” format.
However, when a claim cites the use of an old composition or structure and the “use” is directed
to a result or property of that composition or structure, then the claim is anticipated. 120 In this
regard, it is worth mentioning that it is unclear of how many of intellectual creative steps is
required to be constitute a “process” within meaning of “process of use”. Nonetheless, it is
uncontested that, through ordinary meaning, there must be a series of steps taken to introduce a
special way to use the subject-matter to cause a result which be useful, non-obvious to a person
who have ordinary skill in relevant art, and novel as to not be anticipated by other processes. 121
V. Conclusion
The purpose of this research was to provide a comparative study of the legal status of
new use patents at international, regional and national levels, based on current and historical
legal facts by questioning their appropriate treatments in hopes of arriving at a conclusion that
posits that new uses, like other kinds of inventions, must involve the element of “creativity” as
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the main core of contrivances. Proving the act of “creation” for new uses as key point in
providing patent protection depends on applying an appropriate legal frame of patents. The
essentials of customary patent law, quiddity of new uses, avoiding admixture with concept of
“discovery” and the experiences of proponent jurisdictions are meant to address that the most
appropriate legal format is applying the format of “process” proposing the new uses as an
independent and patentable invention. Accordingly, providing a comprehensive approach which
could cover all probable new use cases, not only for proponents but also for opponents, requires
adjusting the legal definition of “process” to include “process of use” and “method of use”
through specifying its constitutional elements. Hence, for the purpose of excluding the new uses,
the opponent jurisdictions should define the term “process” narrowly and full-conditionally as far
as it does not include the “uses”. In contrast, the proponents should define “process” as broad as
to include the “uses” (e.g. one step processes) as far as they are intended; i.e. by solidifying or
softening the terms of constitution.
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